PRESS RELEASE

September 23rd, 2024 (Shanghai) — We are glad to announce that Hong Seok Choi, Business Development…

With positive phase II interim data in NSCLC, Abion to advance MET-TKI to combo trial…

https://www.hankyung.com/it/article/202305118801i ABION, a precision oncology drug development company (CEO Shin Young Khee, KRX 203400), announced…

https://www.news1.kr/articles/5017542 Securing Cases of Partial Response (PR) in Initial Patients ABION (CEO Shin Young khee,…

http://www.biospectator.com/view/news_view.php?varAtcId=18416 ABION (CEO Shin Young khee, KRX 203400) announced on the 6th that it will…